PT3240538T - Uso de masitinib para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica - Google Patents

Uso de masitinib para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica

Info

Publication number
PT3240538T
PT3240538T PT177121753T PT17712175T PT3240538T PT 3240538 T PT3240538 T PT 3240538T PT 177121753 T PT177121753 T PT 177121753T PT 17712175 T PT17712175 T PT 17712175T PT 3240538 T PT3240538 T PT 3240538T
Authority
PT
Portugal
Prior art keywords
masitinib
treatment
lateral sclerosis
amyotrophic lateral
patient subpopulation
Prior art date
Application number
PT177121753T
Other languages
English (en)
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of PT3240538T publication Critical patent/PT3240538T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT177121753T 2016-03-25 2017-03-24 Uso de masitinib para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica PT3240538T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16162490 2016-03-25

Publications (1)

Publication Number Publication Date
PT3240538T true PT3240538T (pt) 2021-12-07

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177121753T PT3240538T (pt) 2016-03-25 2017-03-24 Uso de masitinib para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica

Country Status (20)

Country Link
US (1) US10092564B2 (pt)
EP (1) EP3240538B1 (pt)
JP (2) JP7250312B2 (pt)
KR (1) KR102293847B1 (pt)
CN (1) CN108883108B (pt)
AU (1) AU2017236177B2 (pt)
BR (1) BR112018069515A2 (pt)
CA (1) CA3018635C (pt)
DK (1) DK3240538T3 (pt)
EA (1) EA038531B1 (pt)
ES (1) ES2899929T3 (pt)
HU (1) HUE057398T2 (pt)
IL (1) IL261856B (pt)
MX (1) MX2018011349A (pt)
NZ (1) NZ745778A (pt)
PL (1) PL3240538T3 (pt)
PT (1) PT3240538T (pt)
SG (1) SG11201808106YA (pt)
SI (1) SI3240538T1 (pt)
WO (1) WO2017162884A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN109846862A (zh) 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA3033079A1 (en) * 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
ES2848720T3 (es) 2016-11-25 2021-08-11 Genuv Inc Composición para promover la diferenciación y la protección de células madre neurales y método para inducir la regeneración neural utilizando la misma
MX2019011547A (es) * 2017-03-28 2019-11-28 Novartis Ag Nuevos metodos para el tratamiento de la esclerosis multiple.
MX2019014343A (es) * 2017-05-30 2020-08-03 Deciphera Pharmaceuticals Inc Uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-n aftiridin-3-il]-2-fluorofenil]-3-fenilurea y analogos para el tratamiento de canceres asociados con anomalias geneticas en el receptor alfa del factor de crecimiento derivado de plaquetas.
WO2019173361A2 (en) 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
WO2020010049A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation POWDERED FORMULATIONS OF CROMOLYN SODIUM AND α-LACTOSE
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP4726486B2 (ja) 2002-08-02 2011-07-20 アブ サイエンス 2−(3−アミノアリール)アミノ−4−アリール−チアゾールおよびそれらのc−kit阻害薬としての使用法
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
AR080933A1 (es) 2010-04-20 2012-05-16 Ab Science Tratamiento de esclerosis multiple con masitinib
EA028060B1 (ru) 2011-07-13 2017-10-31 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
BR112015007144A2 (pt) * 2012-10-04 2017-12-12 Ab Science uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
EP3388436B1 (en) * 2013-03-15 2020-08-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015063318A1 (en) 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
AU2017236177A1 (en) 2018-09-20
EA201800499A1 (ru) 2019-03-29
CN108883108A (zh) 2018-11-23
SG11201808106YA (en) 2018-10-30
JP2022037132A (ja) 2022-03-08
US20180117037A1 (en) 2018-05-03
AU2017236177B2 (en) 2022-03-31
HUE057398T2 (hu) 2022-05-28
EP3240538B1 (en) 2021-09-29
BR112018069515A2 (pt) 2019-04-16
CA3018635C (en) 2023-09-26
IL261856B (en) 2022-04-01
SI3240538T1 (sl) 2022-02-28
CA3018635A1 (en) 2017-09-28
NZ745778A (en) 2022-07-01
JP7250312B2 (ja) 2023-04-03
US10092564B2 (en) 2018-10-09
CN108883108B (zh) 2021-08-06
DK3240538T3 (da) 2021-12-06
PL3240538T3 (pl) 2022-01-31
WO2017162884A1 (en) 2017-09-28
JP2019515884A (ja) 2019-06-13
KR20180125966A (ko) 2018-11-26
IL261856A (en) 2018-10-31
EP3240538A1 (en) 2017-11-08
EA038531B1 (ru) 2021-09-10
ES2899929T3 (es) 2022-03-15
KR102293847B1 (ko) 2021-08-26
MX2018011349A (es) 2019-02-07

Similar Documents

Publication Publication Date Title
IL261856B (en) Use of masitinib to treat a subpopulation of amyotrophic lateral sclerosis patients
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
IL253945A0 (en) kdm1a inhibitors to treat the disease
IL272444A (en) Compounds, their salts and methods for treating diseases
IL275482A (en) Asketamine for the treatment of depression
IL268694A (en) Treatment of schizophrenia
IL270752B (en) Pyrrolopyridine-aniline compounds for the treatment of skin disorders
IL254266B (en) Glucosylceramide synthase inhibitors for the treatment of diseases
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
HK1252207A1 (zh) 一種組合物在製備治療肌萎縮性側索硬化症藥物中的應用
HK1258994A1 (zh) 用於疾病治療的方法
ZA201902385B (en) Compounds and methods for diagnosis and treatment of viral infections
PT3286317T (pt) Inibidor de dinamina 2 para o tratamento de distrofia muscular de duchenne
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
IL261116A (en) A drug for the treatment of diabetic foot infections
IL268187A (en) Use of Snickepok to treat stroke
HK1259373A1 (zh) 用於治療糖尿病的藥物製劑
IL259381B (en) Miravegron for the treatment of retinal diseases
EP3310310A4 (en) DEVICE FOR TREATING MENIÈRE DISEASE
IL269681A (en) New methods for treating multiple sclerosis
EP3448869A4 (en) AZASTEROIDS FOR TUBERCULOSIS TREATMENT
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
EP3094330A4 (en) Treatment of crohn's disease using low doses of laquinimod
ZA201901948B (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
AU2015901877A0 (en) Treatment of amyotrophic lateral sclerosis